3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Neoplasms
15
Endometrial Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Rectal Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Osteosarcoma
2
Locally Advanced Rectal Cancer (LARC)
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Interventions
pembrolizumab
5
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
cabozantinib
3
Nivolumab
3
cemiplimab
2
Ipilimumab
2
sodium thiosulfate
1
relacorilant
1
lenvatinib
1
fludarabine phosphate
1
dostarlimab
1
Radiation
1
Mitotane
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Floxuridine
1
E-7386
1
Drug Therapy
1
Dexamethasone
1
Cytoreduction Surgical Procedures
1
Cyclophosphamide
1
Cisplatin
1
CTLA-4 Antigen
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adrenocortical Carcinoma
×
dostarlimab
×
1 year
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled